Susan Lupton

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi et autres

BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is …

gb, ch, ca (code pays fourni par la source)

Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer

Adrian Murray Brunt, Susan Lupton, Karen Thorley, J. Handley

AIM: A comparison of techniques, CT planning of the supraclavicular fossa and field based simulation. We highlight CT planned SCF radiotherapy which would be useful for a centre introducing the technique. BACKGROUND: Development of radiotherapy technique includes a move from field-based simulation …

gb (code pays fourni par la source)

AMERICAN INDIAN TRIBAL CODES

Susan Lupton

No abstract available for this article.